TriangleSafusidenib (NCT07703436)
Safusidenib trial for Grade 2 IDH1-mutant Glioma (NCT07703436). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with grade 2 or 3 IDH1-mutant glioma that progressed during vorasidenib treatment. Previous glioma treatment must be limited to surgery and vorasidenib; immediate chemotherapy or radiation must not be needed.
The idea: safusidenib blocks mutant IDH1, reducing production of 2-hydroxyglutarate, a substance that disrupts cell maturation. Participants take 250 mg orally twice daily. Researchers assess tumor response and safety after progression on the earlier inhibitor.
This phase 2 study plans 40 patients. Nuvation Bio sponsors it. NYU Langone in New York is the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.